Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Zoe Memel,Ashwini Arvind,Oluwatoba Moninuola,Lisa L. Philpotts,Raymond T. Chung,Kathleen E. Corey,Tracey G. Simon +6 more
TL;DR: Aspirin use was associated with a significant reduction in HCC risk and benefits appeared to increase with increasing dose and duration of aspirin use, as well as in subgroup analyses.
Journal ArticleDOI
Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis
TL;DR: This systematic review identified an important gap in randomized controlled trial evidence for using 101–325 mg aspirin daily in diabetes and concluded available data does not support an aspirin dose-response effect for prevention of cardiovascular events in diabetic patients.
Journal ArticleDOI
Migraine and cardiovascular disease in women and the role of aspirin: Subgroup analyses in the Women’s Health Study
TL;DR: In post-hoc subgroup analyses of the Women’s Health Study, aspirin had similar protective effects on ischaemic stroke for women with or without migraine, while data suggest that women with MA on aspirin had increased risk of MI.
Journal ArticleDOI
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
TL;DR: The second-generation P2Y(12) inhibitor ticagrelor plus aspirin demonstrated superior ischemic outcomes, including reduction in total mortality, versus clopidogrel plus aspirin, but event rates remain high, and major bleeding not related to coronary artery bypass grafting is increased.
Journal ArticleDOI
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
Marc P. Bonaca,Shinya Goto,Deepak L. Bhatt,P. Gabriel Steg,Robert F. Storey,Marc Cohen,Erica L. Goodrich,Laura Mauri,Ton Oude Ophuis,Michail Ruda,Jindrich Spinar,Ki-Bae Seung,Dayi Hu,Anthony J. Dalby,Eva C. Jensen,Peter Held,David A. Morrow,Eugene Braunwald,Marc S. Sabatine +18 more
TL;DR: High-risk patients with prior myocardial infarction are at risk for stroke, and the addition of ticagrelor 60 mg twice daily significantly reduced this risk without an excess of hemorrhagic stroke but with more major bleeding.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.